Strong Wegovy data will help Novo Nordisk access heart failure market

25 August 2023
novo_nordisk_big

Danish diabetes giant Novo Nordisk (NOV: N) has announced results from the Phase III STEP HFpEF trial of semaglutide.

Compared with placebo, a 2.4mg dose of the GLP-1 agonist led to significant reductions in heart failure-related symptoms and physical limitations.

There were also improvements in exercise function and greater weight loss for adults with heart failure with preserved ejection fraction (HFpEF) and obesity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical